On Wednesday, Mizuho (NYSE:MFG) initiated coverage on shares of McKesson Corporation (NYSE:NYSE:MCK) with a Neutral rating, setting a price target of $630. The initiation comes after the company has significantly expanded its business model, particularly with the creation of a substantial oncology platform valued at approximately $35 billion.
According to InvestingPro data, McKesson currently commands a market capitalization of $78.28 billion and maintains a "GREAT" financial health score of 3.15/5, indicating robust operational performance. This new venture is expected to provide McKesson with a long-term growth rate above its peers, with projections of a 12-14% increase in earnings per share (EPS) compound annual growth rate (CAGR) over the next three to five years.
The company's enhanced focus on oncology was highlighted during an analyst meeting in early November, which bolstered investor confidence in McKesson's ability to meet its fiscal year 2025 guidance. Since the announcement of the analyst meeting on September 24, 2024, McKesson's stock has experienced a rally, with shares increasing by roughly 30%.
The recent surge in the stock's performance is a factor in Mizuho's valuation. The stock is currently trading near its 52-week high of $637.51, with a year-to-date return of 34.1%. Despite the recent rally, InvestingPro's Fair Value analysis suggests the stock may still be slightly undervalued, with additional upside potential available to investors.
Mizuho's price target is based on a price-to-earnings (P/E) ratio of 16 times the calendar year 2026 EPS estimate of $39.50. This valuation is consistent with one of McKesson's competitors, Cardinal Health (NYSE:CAH) (COR), and includes a slight premium compared to another competitor, AmerisourceBergen (NYSE:COR) (CAH).
Despite recent positive developments and the company's strong prospects, Mizuho has opted for a Neutral rating due to the current stock valuation. The stock currently trades at a P/E ratio of 31.97, reflecting investors' confidence in McKesson's growth trajectory and market position.
The coverage initiation by Mizuho reflects a careful assessment of McKesson's current market position and growth potential, particularly in the oncology sector. It also takes into account the significant appreciation in the company's stock price over the past few months, which may temper short-term upside potential. As the market absorbs this new information, investors will likely monitor McKesson's performance in relation to the expectations set forth by the analysts.
In other recent news, McKesson Corporation reported its second-quarter fiscal 2025 results, providing an overview of the company's financial performance and operational forecasts. The earnings call, led by CEO Brian Tyler and CFO Britt Vitalone, emphasized the company's expectations for its future operations and financial outcomes. While expressing confidence in the company's direction, they also acknowledged the potential risks that could affect these outcomes.
In the meantime, Jefferies, a reputable analyst firm, has raised its price target for McKesson to $715, maintaining a Buy rating for the company's shares. This adjustment followed a conference where McKesson's CFO, Britt Vitalone, shared insights that reinforced Jefferies' positive stance on the company. Key points included McKesson's focus on Oncology and Biopharma Services as a critical growth strategy, the anticipated financial benefits from the pending FCS deal, and the potential for Cell and Gene therapies to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.